Intra-cellular therapies announces positive topline results from study 403 evaluating lumateperone as monotherapy in patients with major depressive disorder with mixed features and bipolar depression with mixed features

Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the montgomery asberg depression rating scale (madrs) for each patient population including:
ITCI Ratings Summary
ITCI Quant Ranking